• Wondering if Insulet at around US$175 still reflects its true worth, or if the recent price is out of sync with underlying value.
• Over the past year, the share price has delivered a 31.9% loss, with returns of 38.1% year to date, 14.3% over the past month, and 7.7% over the last week adding to the pressure on sentiment.
• These moves have played out against a backdrop of ongoing attention on Insulet's position in the medical equipment space and investor focus on how its growth profile compares with other healthcare names. Headlines around competition in diabetes care and changing expectations for medical technology spending have kept questions about what counts as a fair price for Insulet front and center.
• Simply Wall St currently gives Insulet a valuation score of 2 out of 6, so next it makes sense to look at how different valuation tools, such as discounted cash flow and multiples, line up, before finishing with a broader way to think about what the market might be missing.

Insulet scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Insulet Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting future cash flows and then discounting them back to today using a required return. It aims to answer what those future dollars are worth in today’s terms.

For Insulet, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow stands at about $375.9 million. Analysts and extrapolations point to projected Free Cash Flow of $914.0 million in 2030, with intermediate years such as 2026 and 2027 modeled at $458.6 million and $563.7 million respectively, all in $ and adjusted in present value terms.

Bringing these projected cash flows back to today, Simply Wall St’s DCF output suggests an estimated intrinsic value of about $290.29 per share. Compared with the recent share price around $175, this implies Insulet trades at about a 39.7% discount to that modeled value. On this specific cash flow view, the stock appears to be trading below that estimated intrinsic value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Insulet is undervalued by 39.7%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Insulet Price vs Earnings

For profitable companies, the P/E ratio is a useful way to connect what you pay for each share with the earnings that support that price. It helps you see how many dollars of share price the market is attaching to each dollar of current earnings.

What counts as a reasonable P/E will usually vary with growth expectations and risk. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or greater uncertainty can point to a lower one.

Insulet currently trades on a P/E of 49.06x. That sits above the Medical Equipment industry average of 23.56x and also above the peer group average of 35.39x. Simply Wall St’s Fair Ratio for Insulet is 32.01x, which is its own estimate of a suitable P/E once factors such as earnings growth, industry, profit margins, market cap and company specific risks are taken into account.

The Fair Ratio offers a more tailored anchor than a simple comparison with peers or the wider industry because it aims to adjust for Insulet’s own profile rather than relying only on broad group averages. Compared with the current 49.06x P/E, the 32.01x Fair Ratio points to Insulet trading above that implied fair level.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your Insulet Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story to the numbers by combining your view on Insulet’s business drivers with a concrete forecast for revenue, earnings and margins. This links that story to a Fair Value that you can compare with today’s price on the Community page, where millions of investors share views. For Insulet you might see one Narrative built around a higher Fair Value near US$435 that leans on faster adoption of Omnipod systems and international expansion, and another closer to US$239 that leans on execution risks and tougher competition. As new information such as Omnipod device updates, clinical data or guidance arrives, these Narratives refresh automatically so you can quickly see whether your chosen Fair Value still lines up with the current share price and decide if the gap between price and value still fits your view.

Do you think there's more to the story for Insulet? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.